A mobile digital application that uses a cognitive behavioral theory (CBT) model to help individuals struggling with perinatal mood and anxiety disorders.
Background: Approximately 10-24% of women report peripartum mood and anxiety disorders (PMADs) as a complication of pregnancy. Untreated PMADs have devastating outcomes on the physical and mental health of both the mother and the child. While effective modalities, e.g., specialized medications such as allopregnanolone derivatives, collaborative care and integrated treatment models, and perinatal access programs, have been developed, studies show that only up to 3% women with PMADs receive adequate treatment. Currently, most treatment-related services for PMADs are limited to the healthcare system, where common barriers for providers and individuals struggling with PMADs include insurance, transportation, trust in the healthcare system, stigma associated with PMADs, and societal attitudes towards the postpartum period.
Technology Overview: The mobile digital application was developed as part of a larger project to deliver a community-based therapeutic intervention for pregnant and postpartum individuals struggling with PMADs. Employing cognitive behavioral theory (CBT) models that were successfully used for smoking cessation and insomnia, the application is based on a manual that was originally developed by the World Health Organization and culturally adapted to the United States. It offers two interfaces – one for Mothers (to track practice work and identify resources) and one for Health Care Workers (to help with implementation).
https://suny.technologypublisher.com/files/sites/adobestock_190591075.jpeg
Advantages: • Addresses one of the major health risks facing women today. • Compatible with both IOS and Android systems. • Available in Spanish.
Applications: The primary application for this technology is to help individuals struggling with perinatal mood and anxiety disorders.
Intellectual Property Summary: Copyrightable software
Stage of Development: TRL 6
Licensing Status: This technology is available for licensing.
Licensing Potential: This technology would be of interest to facilities involved in research for developing pharmaceuticals that treat breast cancer. These include: • Pharmaceutical manufacturers. • Universities. • Medical research laboratories.